1. TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T‐CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T‐CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY. (12th June 2019) Authors: Witzig, T.; Sokol, L.; Kim, W.; Foss, F.; Jacobsen, E.; de la Cruz Vincente, F.; Caballero, D.; Advani, R.; Roncero Vidal, J.M.; Marin‐Niebla, A.; Rodriguez Izquierdo, A.; de Ona Navarrete, R.; Terol, M.J.; Domingo‐Domenech, E.; Rodriguez, M.; Piris, M.A.; Bolognese, J.; Janes, M.R.; Burrows, F.;... Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. HNSCCs overexpressing wild-type HRAS are sensitive to combined tipifarnib and alpelisib treatment. (October 2022) Authors: Soifer, H.; Mishra, V.; Malik, S.; Smith, A.; Chan, S.; Kessler, L.; Burrows, F.; Leoni, M.; Saunders, A.; Dale, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S58 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Antitumor activity of tipifarnib and PI3K pathway inhibitors in HRAS-associated head and neck squamous cell carcinoma. (October 2020) Authors: Burrows, F.; Shivani, M.; Wang, Z.; Chan, S.; Gilardi, M.; Gutkind, S. Journal: European journal of cancer Issue: Volume 138(2020)Supplement 2 Page Start: S43 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The Medication Error Minimisation Scheme in a tertiary intensive care unit 2009–2014. Issue 1 (February 2015) Authors: Breeding, J.; Welch, S.; Beckett, H.; Burrows, F.; Buscher, H.; Wong, K.; Whittam, S.; Mackay, B.; Mathews, N.; Sakowicz, V.; McCann, K.; Otani, C. Journal: Australian critical care Issue: Volume 28:Issue 1(2015) Page Start: 46 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. KO-947, a potent and selective ERK inhibitor with slow dissociation kinetics. (December 2016) Authors: Kessler, L.; Chen, J.; Guo, X.; Hensen, R.; Patricelli, M.; Li, S.; Thach, C.; Darjania, L.; Li, S.; Wu, T.; Hu-Lowe, D.; Yao, Y.; Zarieh, A.; Janes, M.; Ely, T.; Burrows, F.; Zhang, J.; Li, L.; Ren, P.; Liu, Y. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S126 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Sound and light in ICU during different environmental conditions. Issue 2 (March 2018) Authors: Breeding, J.; Buscher, H.; Nair, P.; Baker, N.; Frost, C.; Mathews, N.; McGauley, J.; Welch, S.; Whittam, S.; Burrows, F. Journal: Australian critical care Issue: Volume 31:Issue 2(2018) Page Start: 135 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PRELIMINARY RESULTS FROM AN OPEN‐LABEL, PHASE II STUDY OF TIPIFARNIB IN RELAPSED OR REFRACTORY PERIPHERAL T‐CELL LYMPHOMA. (June 2017) Authors: Witzig, T.; Sokol, L.; Jacobsen, E.; Advani, R.; Mondejar, R.; Piris, M.; Burrows, F.; Melvin, C.; Mishra, V.; Scholz, C.; Gualberto, A. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗